Joseph Eid, M.D.

Prior to joining Geron, Dr. Eid served as President, Research and Development for Dragonfly Therapeutics, Inc., with overall responsibilities for the company’s discovery and clinical research strategy and execution. Before that, he served as EVP, Chief Medical Officer at Luzsana Bio, a subsidiary of Hengrui Pharmaceuticals.

Prior to his biotech leadership roles, Dr. Eid served as Senior Vice President and Head, Global Medical Affairs for Bristol Myers Squibb (BMS), where from 2017 to 2021 he led a very large global market-based medical affairs organization that included more than 2,500 people reporting into him from over 70 markets across four therapeutic franchises. Prior to BMS, he spent nine years at Merck, first at Merck Research Labs, where he led the first-in-human strategy of their global KEYTRUDA® program, including oversight of the clinical, regulatory, and manufacturing planning and execution that led to a first-in-class Biologics License Application (BLA) filing and approval in the U.S. He subsequently took a role at Merck Global Human Health, where he was tasked with building the oncology global medical affairs team from the ground up. Dr. Eid started his pharmaceutical career at Hoffmann La Roche, where he was responsible for both early- and late-stage assets and led several clinical teams.